BioWorld

May 6, 2005

View Archived Issues

Cephalon's Oravescent Fentanyl Hits Primary Endpoint In Phase III

In reporting positive results from a Phase III study of Oravescent fentanyl, Cephalon Inc. said it is on track to submit a new drug application to the FDA next quarter. (BioWorld Today) Read More

Bayhill Therapeutics Raises $35M In Series B For Autoimmune Drugs

Read More

Ironies Abound In Science, Tetrahydrocannabinol Rules

Read More

Avidia Advancing Lead Product Through $28.5M Series B Round

Read More

Other News To Note

Read More